● Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Condition: Relapsed or Refractory Multiple Myeloma · Previously Treated Amyloid Light-chain (AL) Amyloidosis · Sponsor: Janssen Research & Development, LLC

PhasePhase 1

Planned participants180

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).

This description comes directly from the study's public registry record.

Talk to the study team

Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com

Always discuss trial participation with your own doctor first.

Locations (29)

City of Hope	Duarte, California, United States	Recruiting
City of Hope Orange County Lennar Foundation Cancer Center	Irvine, California, United States	Recruiting
University of California San Francisco	San Francisco, California, United States	Recruiting
Colorado Blood Cancer Institute	Denver, Colorado, United States	Recruiting
Icahn School of Medicine at Mt. Sinai	New York, New York, United States	Recruiting
Memorial Sloan Kettering Cancer Center	New York, New York, United States	Recruiting
Levine Cancer Institute	Charlotte, North Carolina, United States	Recruiting
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine	Philadelphia, Pennsylvania, United States	Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting
UZ Antwerpen	Edegem, Belgium	Recruiting
UZ Gent	Ghent, Belgium	Recruiting
CHU de Liege	Liège, Belgium	Recruiting

+ 17 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05652335